Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHEDLOCK-2 CAR-T cells
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
SHEDLOCK-2 CAR-T cells are an investigational autologous chimeric antigen receptor (CAR) T-cell therapy designed to treat multiple myeloma by targeting B-cell maturation antigen (BCMA). Developed using the SHEDLOCK (Shedding Deterrent Locked-in) platform, these cells are engineered to secrete a naturally derived γ-secretase-modulatory peptide (nxP). This peptide inhibits the γ-secretase-mediated cleavage of BCMA from the surface of malignant plasma cells, thereby reducing the levels of soluble BCMA (sBCMA) that can act as a decoy and maintaining high surface antigen density for CAR engagement. Beyond antigen stabilization, SHEDLOCK-2 cells are programmed for enhanced metabolic fitness and longevity, exhibiting preserved telomere integrity, reduced expression of senescence markers like p21, and a shift toward oxidative phosphorylation, which collectively result in improved persistence and a central memory phenotype.
- Other names
- Shedding Deterrent Locked-in CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)GSEC (Gamma-Secretase Complex)
Beyond the preview
Go deeper on SHEDLOCK-2 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHEDLOCK-2 CAR-T cells.